|
|
| Name of Committee | Orthopaedic and Rehabilitation Devices Panel |
| Date and Time | The meeting was held on the following dates:
Feb 22, 2007 8:00 AM - 5:00 PM
|
| Location | Hilton Washington DC North/Gaithersburg, Salons A, B and C
620 Perry Parkway
Gaithersburg
, MD |
| Contact Information | Ronald P. Jean, Center for Devices and Radiological Health (HFZ-410), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD, 20850, 240-276-3676, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 3014512521. Please call the Information Line for up-to-date information on this meeting. |
| Agenda | The committee will discuss, make recommendations and vote on a premarket approval application (PMA) for the Cormet 2000 Hip Resurfacing System, sponsored by Corin U.S.A. This system is intended for use in resurfacing hip arthroplasty for reduction or relief of pain and/or improved hip function in skeletally mature patients with non-inflammatory degenerative arthritis or inflammatory arthritis. FDA intends to make background material available to the public no later than 1 business day before the meeting. If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA’s Web site after the meeting. Background material is available at http://www.fda.gov/ohrms/dockets/ac/acmenu.htm, click on the year 2007 and scroll down to the appropriate advisory committee link. |
| Procedure | Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person on or before February 8, 2007. Oral presentations from the public will be scheduled for 30 minutes at the beginning of the committee deliberations and for 30 minutes near the end of the deliberations on February 22, 2007. Those desiring to make formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before January 31, 2007. Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by February 1, 2007. |
| | Persons attending FDA’s advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets. |
| Conduct | FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site at http://www.fda.gov/oc/advisory/ for procedures on public conduct during advisory committee meetings. |
| Related Documents |
| Agenda: | February 22, 2007 Meeting |  |
| Briefing: | February 22, 2007 Meeting |  |
| Minutes: | Minutes for February 22, 2007 Meeting | |
| Notice of Meeting: | February 22, 2007 Meeting | |
| Other: | Nature & Basis Statements of Conflict(s) of Interest; February 22, 2007 Meeting | |
| Other: | Letters to the Record for February 22, 2007 Meeting | |
| Questions: | February 22, 2007 Meeting | |
| Questions: | Draft Questions for February 22, 2007 Meeting | |
| Roster: | February 22, 2007 Meeting | |
| Slides: | February 22, 2007 Meeting | |
| Summary: | February 22, 2007 Meeting | |
| Transcript: | Transcript for February 22, 2007 Meeting |  |
|
| Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2). |
|
